» Articles » PMID: 25912546

Dystonia in an Adolescent on Risperidone Following the Discontinuation of Methylphenidate: a Case Report

Overview
Specialty Psychiatry
Date 2015 Apr 28
PMID 25912546
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

Attention-deficit/hyperactivity disorder (ADHD) is a neurodevelopmental disorder with common comorbidities that include oppositional defiant disorder, conduct disorder, anxiety disorder, and affective disorders. Because of these comorbidities, drug combination treatments and drug-drug interactions are becoming increasingly more frequent. The present case report describes an acute dystonic reaction following the abrupt discontinuation of methylphenidate from a drug regimen with risperidone. The patient experienced acute dystonic reactions on three separate occasions when he forgot to take his methylphenidate medication. The present report informs clinicians about the possible side effects, such as dystonia, when psychostimulant and antipsychotic drug combinations are altered and suggests that the abrupt cessation of stimulants may lead to the development of movement disorders. Therefore, appropriate care is necessary when changing the dose of a drug or abruptly discontinuing a drug from a combination of psychostimulants and antipsychotics.

Citing Articles

A Rare Phenomenon, Recurrent Acute Dystonia after Withdrawal of 'Methylphenidate-immediate Release Form': A Pediatric Case with ADHD.

Efe A, Cura M, Ozturk Y, Kasak M, Secer S, Yukse D Clin Psychopharmacol Neurosci. 2024; 22(3):544-549.

PMID: 39069696 PMC: 11289597. DOI: 10.9758/cpn.24.1158.


Acute Hyperkinetic Movement Disorders as a Multifactorial Pharmacodynamic Drug Interaction Between Methylphenidate and Risperidone in Children and Adolescents.

Mohamoud M, Chen Q, Croteau D, Cheng C, Burkhart K, Volpe D J Clin Psychopharmacol. 2022; 42(3):238-246.

PMID: 35489029 PMC: 9060383. DOI: 10.1097/JCP.0000000000001547.


Intentional Discontinuation of Psychostimulants Used to Treat ADHD in Youth: A Review and Analysis.

Lohr W, Wanta J, Baker M, Grudnikoff E, Morgan W, Chhabra D Front Psychiatry. 2021; 12:642798.

PMID: 33959050 PMC: 8093505. DOI: 10.3389/fpsyt.2021.642798.


Movement disorders and use of risperidone and methylphenidate: a review of case reports and an analysis of the WHO database in pharmacovigilance.

Stampfli D, Weiler S, Burden A Eur Child Adolesc Psychiatry. 2020; 30(7):1047-1058.

PMID: 32621088 DOI: 10.1007/s00787-020-01589-2.


Dystonia with MPH/Risperidone Combined Therapy for ADHD.

Millichap J, Yee M Pediatr Neurol Briefs. 2016; 30(1):7.

PMID: 27004141 PMC: 4798857. DOI: 10.15844/pedneurbriefs-30-1-6.

References
1.
Silvestri S, Seeman M, Negrete J, Houle S, Shammi C, Remington G . Increased dopamine D2 receptor binding after long-term treatment with antipsychotics in humans: a clinical PET study. Psychopharmacology (Berl). 2000; 152(2):174-80. DOI: 10.1007/s002130000532. View

2.
Benjamin E, Salek S . Stimulant-atypical antipsychotic interaction and acute dystonia. J Am Acad Child Adolesc Psychiatry. 2005; 44(6):510-2. DOI: 10.1097/01.chi.0000159166.96967.13. View

3.
McLaren J, Cauble S, Barnett R . Aripiprazole induced acute dystonia after discontinuation of a stimulant medication. J Clin Psychopharmacol. 2010; 30(1):77-8. DOI: 10.1097/JCP.0b013e3181c92eb2. View

4.
Shen Y . Amphetamine as a risk factor for aripiprazole-induced acute dystonia. Prog Neuropsychopharmacol Biol Psychiatry. 2008; 32(7):1756-7. DOI: 10.1016/j.pnpbp.2008.07.014. View

5.
Sabuncuoglu O . Risperidone-to-methylphenidate switch reaction in children: three cases. J Psychopharmacol. 2007; 21(2):216-9. DOI: 10.1177/0269881107069466. View